Treats migraine with or without aura. ANDA 204730, held by Glenmark Pharms Ltd. Frovatriptan Succinate.
As of Nov 16, 2026, ANDA 204730 (Frovatriptan Succinate), held by Glenmark Pharms Ltd, was first approved by FDA on Mar 11, 2016, with 1 approved supplement and 0 published complete response letters.
Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 11, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Frovatriptan SuccinateEQ 2.5MG BASE · tablet;oral | Frovatriptan Succinate | Rx |
| Oct 24, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 11, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters